| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Naftidrofuryl | Naftidrofuryl EP Impurity A | VE006521 | View CAS 25379-26-4 |
| Naftidrofuryl | Naftidrofuryl EP Impurity B | VE006522 | View |
| Naftidrofuryl | Naftidrofuryl EP Impurity C (Free Base) | VE006523 | View CAS 115025-98-4 |
| Naftidrofuryl | Naftidrofuryl EP Impurity D | VE006524 | View |
| Naftidrofuryl | Naftidrofuryl EP Impurity E | VE006525 | View |
| Naftidrofuryl | Naftidrofuryl EP Impurity F | VE006526 | View CAS 41359-72-2 |
| Catalogue No. | VE006523 |
| CAS No. | 115025-98-4 |
| Molecular Formula | C30H34NO2 |
| Molecular Weight | 439.59 |
| Parent drug | Naftidrofuryl |
| IUPAC Name | 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-[(naphthalen-1-yl)methyl]propanoate |
| Synonyms | N/A |
| References | Sci-Hub, Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication, 10.1002/bjs.8895. (2012). Retrieved December 2, 2021, from Hkvisa.net website: https://sci-hub.hkvisa.net/10.1002/bjs.8895 ? |
| Status | Under Development |
| ListName | Naftidrofuryl EP Impurity C (Free Base) |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
